TEMPE, Ariz., Oct. 16 /PRNewswire/ -- A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, Christ Hospital in Cincinnati, and Medivation Inc. in San Francisco, the team discovered very low concentration of bioactive BNP in plasma obtained from patients with heart failure, and presented direct structural evidence for several proteolytically degraded forms of BNP in these patients.
"Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," says Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream. "This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling," adds Niederkofler.
"This work is going to add greater clarity to how clinicians and researchers approach natriuretic peptides and heart failure," says Dr. Roger Mills, from Ortho McNeil Jannsen Scientific Affairs. "The results may provide an explanation for the 'natriuretic paradox' of increased natriuretic hormone levels with blunted effects in heart failure patients."
Intrinsic Bioprobes Inc. is a privately held Biotechnology Company
focused on developing mass spectrometry-based assays and platforms for
rapid and sensitive protein biomarker analysis. The company's proprietary
technologies consist of Mass Spectrometric Immunoassay (MSIA), a
high-performance immunoassay combining micro-scale immunoaffinity capture
and mass spectrometry for high throughput analysis of proteins from complex
biological matrices, and Bioreactive Mass Spectrometer Probes (BRP),
devices for rapid, sensitive and accurate protein characterization. These
root technologies are incorporated into the MASSAY System, a high
throughput mass spectrometry platform for rapid proteome analysis. For more
information about Intrinsic Bioprobes Inc., please visit
Intrinsic Bioprobes Inc.
Monte Cain, Director of Business Development
Tel.: (480) 804-1778
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Intrinsic Bioprobes Inc.|
Copyright©2008 PR Newswire.
All rights reserved